A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Mise à jour : Il y a 4 ans
Référence : NCT01706926

Femme et Homme

Extrait

The primary objective of this study is to evaluate the efficacy of 3 subcutaneous doses of mavrilimumab compared with placebo in combination with methotrexate (MTX) in subjects with moderate-to-severe adult onset Rheumatoid Arthritis (RA).


Critère d'inclusion

  • Rheumatoid Arthritis


Liens